Francesca Rizzo

Ms. Francesca Rizzo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
FRFrancesca Rizzo
Francesca Rizzo
ACAntonella Centonze
Antonella Centonze
GCGianfranco Cavallaro
Gianfranco Cavallaro
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
ASAntonio Scilimati
Antonio Scilimati
Diffuse intrinsic pontine glioma (DIPG), affecting children aged 4–7 years, is a rare, aggressive tumor that originates in the pons and then spreads to nearby tissue. DIPG is the leading cause of death for pediatric brain tumors due to its infiltrative nature and inoperability. Radiotherapy has only a palliative effect on stabilizing symptoms. In silico and preclinical studies identified ONC201 as a cytotoxic agent against some human cancer cell lines, including DIPG ones. A single-crystal X-ray analysis of the complex of the human mitochondrial caseinolytic serine protease type C (hClpP) and ONC201 (PDB ID: 6DL7) allowed hClpP to be identified as its main target. The hyperactivation of hClpP causes damage to mitochondrial oxidative phosphorylation and cell death. In some DIPG patients receiving ONC201, an acquired resistance was observed. In this context, a wide program was initiated to discover original scaffolds for new hClpP activators to treat ONC201-non-responding patients. Harmaline, a small molecule belonging to the chemical class of β-carboline, was identified through Fingerprints for Ligands and Proteins (FLAP), a structure-based virtual screening approach. Molecular dynamics simulations and a deep in vitro investigation showed interesting information on the interaction and activation of hClpP by harmaline.

20 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
OBOlga Maria Baldelli
Olga Maria Baldelli
CFCosimo G. Fortuna
Cosimo G. Fortuna
GCGianfranco Cavallaro
Gianfranco Cavallaro
DADomenico Armenise
Domenico Armenise
ASAntonio Scilimati
Antonio Scilimati

10 July 2021 in Life
Verified
Journal Article
Open access
PDF file
FCFrancesco Capriglia
Francesco Capriglia
FRFrancesca Rizzo
Francesca Rizzo
GPGiuseppe Petrosillo
Giuseppe Petrosillo
VMVeronica Morea
Veronica Morea
GDGiulia D'Amati
Giulia D'Amati
Francesco BruniFrancesco Bruni
Francesco Bruni
The m.3243A>G mutation within the mitochondrial mt-tRNALeu(UUR) gene is the most prevalent variant linked to mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome. This pathogenic mutation causes severe impairment of mitochondrial protein synthesis due to alterations of the mutated tRNA, such as reduced aminoacylation and a lack of post-transcriptional modification. In transmitochondrial cybrids, overexpression of human mitochondrial leucyl-tRNA synthetase (LARS2) has proven effective in rescuing the phenotype associated with m.3243A>G substitution. The rescuing activity resides in the carboxy-terminal domain (Cterm) of the enzyme; however, the precise molecular mechanisms underlying this process have not been fully elucidated. To deepen our knowledge on the rescuing mechanisms, we demonstrated the interactions of the Cterm with mutated mt-tRNALeu(UUR) and its precursor in MELAS cybrids. Further, the effect of Cterm expression on mitochondrial functions was evaluated. We found that Cterm ameliorates de novo mitochondrial protein synthesis, whilst it has no effect on mt-tRNALeu(UUR) steady-state levels and aminoacylation. Despite the complete recovery of cell viability and the increase in mitochondrial translation, Cterm-overexpressing cybrids were not able to recover bioenergetic competence. These data suggest that, in our MELAS cell model, the beneficial effect of Cterm may be mediated by factors that are independent of the mitochondrial bioenergetics.

22 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
FRFrancesca Rizzo
Francesca Rizzo
ACAntonella Centonze
Antonella Centonze
GCGianfranco Cavallaro
Gianfranco Cavallaro
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino
ASAntonio Scilimati
Antonio Scilimati
Diffuse intrinsic pontine glioma (DIPG), affecting children aged 4-7 years, is a rare, aggressive tumor that originates in the pons and then spreads to nearby tissue. DIPG is the leading cause of death for pediatric brain tumors due to its infiltrative nature and inoperability. Radiotherapy has only a palliative effect in stabilizing symptoms. In silico and preclinical studies identified ONC201, as a cytotoxic agent against some human cancer cell lines, including DIPG ones. Single crystal X-ray analysis of the complex of the human mitochondrial caseinolytic serine protease type C (hClpP) and ONC201 (PDB ID: 6DL7) allowed to identify hClpP as its main target. Hyperactivation of hClpP causes damage to mitochondrial oxidative phosphorylation and cell death. In some DIPG patients, receiving ONC201, an acquired resistance was observed. In this context, a wide program was initiated to discover original scaffolds for new hClpP activators to treat ONC201-non-responding patients. Harmaline, a small molecule belonging to the chemical class of β -carboline, was identified through Fingerprints for Ligands and Proteins (FLAP), a structure-based Virtual Screening approach. Molecular dynamics simulations and a deep in vitro investigation showed interesting information on the interaction and activation of hClpP by harmaline.

14 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
ASAntonio Scilimati
Antonio Scilimati
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
DADomenico Armenise
Domenico Armenise
OBOlga Baldelli
Olga Baldelli
ALAnselma Liturri
Anselma Liturri
Maria Grazia PerroneMaria Grazia Perrone
Maria Grazia Perrone
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brainstem tumor affecting children, with median survival under 12 months and no curative treatments. Current therapeutic development centers on ONC201, an imipridone that exhibits clinical activity by selectively activating human caseinolytic protease P ( h ClpP). X-ray analysis of the h ClpP:ONC201 complex offers insights into optimizing the chemical structure of ONC201. Based on this, we designed and synthesized simplified piperazine-based analogs, identifying the polyfunctional chemotype 26 (DA29) through the systematic screening of five new series featuring piperazine-, piperazine-1-one (exocyclic carbonyl), piperazine-1,4-dione (exocyclic carbonyls), piperazine-2-one (endocyclic carbonyl), and piperazine-2,5-dione (endocyclic carbonyls) core scaffolds. The X-ray structure of the h ClpP: 26 (DA29) complex demonstrated a direct binding to the enzyme’s hydrophobic pocket, present at the apical domain, consistent with its strong proteolytic activation. Permeability studies under dynamic flow conditions indicated that 26 (DA29) can cross cellular barriers modeling drug transport, suggesting potential brain tumor penetration. Mechanistic studies showed that 26 (DA29) activates h ClpP, displaces h ClpX from the h ClpXP complex, induces mitochondrial dysfunction and causes ROS accumulation, exerts cytotoxicity and alters lipid profile in patient-derived DIPG cells with validation extended to patient-derived DIPG organoids for personalized medicine. 26 (DA29) does not interact with D2/D3 dopamine receptors as ONC201 does and then is deprived of extrapyramidal collateral effects. Overall, these findings establish a new structural framework for h ClpP-targeted therapy, representing a valuable step towards the development of effective treatments for DIPG.

11 August 2026 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FRFrancesca Rizzo
Francesca Rizzo
ABAdam Ben-Shem
Adam Ben-Shem
MTMarc Timmers
Marc Timmers
TBTill Bartke
Till Bartke
SVSTEPHANE D. VINCENT
STEPHANE D. VINCENT
Laszlo ToraLaszlo Tora
Laszlo Tora
Transcriptional co-activator complexes play essential roles in regulating gene transcription by integrating signals from transcription factors and chromatin. Among these, the SAGA (Spt-Ada-Gcn5 acetyltransferase) and ATAC (Ada Two-A Containing) complexes represent related histone acetyltransferase assemblies that contain both shared and specific subunits. SAGA and ATAC possess similar and divergent enzymatic activities that shape their contributions to transcriptional control. Here, we review emerging evidence that highlights differential interactions of transcriptional activators with SAGA or ATAC and their differential chromatin-reading capabilities through specific recognition of histone modifications. Distinct requirements for SAGA and for ATAC have been observed in gene regulation important for maintaining cellular homeostasis and for oncogenic transformation, indicating that dysregulation of these complexes can contribute to cancer progression. The development of small-molecule inhibitors targeting key components of SAGA and/or ATAC offers promising strategies to disrupt their recruitment and transcriptional activity in cancer cells. Our review dissects the unique and overlapping functions of SAGA and ATAC, which are crucial for understanding regulation by these complexes in order to exploit them as targets in precision oncology.